Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Factors Influencing Complete Remission (CR) Rate in Patients ≥ 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study

Blood (2012) 120 (21): 128.

https://doi.org/10.1182/blood.V120.21.128.128

Published: 2012

Journal Articles

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2012) 120 (21): 1855.

https://doi.org/10.1182/blood.V120.21.1855.1855

Published: 2012

Journal Articles

Kinetics of Engraftment and Predictors of Outcome in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL) After Treatment with Low Dose Total Body Irradiation (TBI) Followed by related or unrelated hematopoietic Stem Cell Transplantation

Karin Hebenstreit, Simona Iacobelli, Ann-Kathrin Eisfeld, MD, Christian Pfrepper, Thoralf Lange, MD, Rainer Krahl, MD, Haifa K. Al-Ali, MD, Cornelia Becker, MD, Wolfram Pönisch, Gerhard Behre, MD, Dietger Niederwieser, MD

Blood (2011) 118 (21): 4532.

https://doi.org/10.1182/blood.V118.21.4532.4532

Published: 2011

Journal Articles

Delayed Processing of Bone Marrow Samples Reveals a Prognostic Pattern of NME mRNA Expression in Cytogenetically Normal AML

Enrica Bach, PhD, Rainer Krahl, MD, Sabine Tschiedel, PhD, Thoralf Lange, Frank Schüler, MD, Haifa K. Al-Ali, MD, Thomas Büchner, MD, Gottfried Doelken, MD, Dietger Niederwieser, MD, Michael Cross, PhD

Blood (2011) 118 (21): 4904.

https://doi.org/10.1182/blood.V118.21.4904.4904

Published: 2011

Journal Articles

Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML

Dietger Niederwieser, MD, Leo F Verdonck, Jan J Cornelissen, MD PhD, Michael Cross, PhD, Rainer Krahl, MD, Thoralf Lange, Vladan Vucinic, Georg Franke, MD, Haifa K. Al-Ali, MD, Gert Ossenkoppele, MD, PhD, Georg Maschmeyer, MD, Gottfried Doelken, MD, Mathias Freund, MD, Norma Peter, Marc Boogaerts, MD, PhD, Alois Gratwohl, MD, Harry C. Schouten, MD, PhD, Bob Lowenberg, MD, PhD

Blood (2011) 118 (21): 2030.

https://doi.org/10.1182/blood.V118.21.2030.2030

Published: 2011

Journal Articles

Adverse Immunologic, Cytogenetic, and Molecular Features of AML in Elderly Patients Could Be Overcome by Allogeneic Hematopoietic Cell Transplantation Following Reduced Intensity Conditioning

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Rainer Krahl, MD, Claudia Nehring, Cornelia Becker, MD, Leanthe Braunert, MD, Sabine Leiblein, Jeanett Edelmann, Georg Franke, MD, Wolfram Poenisch, Thoralf Lange, MD, Dietger Niederwieser, MD

Blood (2011) 118 (21): 3065.

https://doi.org/10.1182/blood.V118.21.3065.3065

Published: 2011

Journal Articles

Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup

Thomas Buchner, MD, Richard F. Schlenk, MD, Markus Schaich, MD, Konstanze Döhner, MD, Rainer Krahl, MD, J\)rgen Krauter, MD, Maria Cristina Sauerland, MSc, Daniela Späth, Michael Kramer, Arnold Ganser, MD, Dietger W Niederwieser, MD, Gerhard Ehninger, MD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD, Hartmut Dohner, MD, Dieter Hoelzer, MD, R\)diger Hehlmann, MD, Verena Hoffmann, MA., Markus Pfirrmann, PhD

Blood (2010) 116 (21): 2175.

https://doi.org/10.1182/blood.V116.21.2175.2175

Published: 2010

Journal Articles

The Ratio of Pre-Transplant Serum Ferritin to the Units of Blood Transfused and Not Serum Hepcidin Strongly Correlates with Outcome After Allogeneic Hematopoietic Cell Transplantation In Patients with AML and MDS.

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Rainer Krahl, MD, Elvira Edel, Claudia Wickenhauser, Mark Westerman, Sabine Leiblein, Uwe Gerd Liebert, Marianne Hehme, Dietger W Niederwieser, MD

Blood (2010) 116 (21): 1307.

https://doi.org/10.1182/blood.V116.21.1307.1307

Published: 2010

Journal Articles

Hematopietic Cell Transplantation after a Low-Dose, Total-Body Irradiation Based Regimen in Elderly Patients with AML: A Multicenter, Multinational, Prospective HOVON/SAKK/OSHO Study.

Dietger Niederwieser, MD, Jan Cornelissen, MD, Haifa-Kathrin Al-Ali, MD, Leo Verdonck, MD, Rainer Krahl, MD, Alois Gratwohl, MD, Claudia Nehring, MD, Cornelia Becker, MD, Wolfram Poenisch, MD, Thoralf Lange, MD, Rainer Storb, MD, Bob Lowenberg, MD

Blood (2006) 108 (11): 321.

https://doi.org/10.1182/blood.V108.11.321.321

Published: 2006

Journal Articles

Pooled Data Analysis of Acute Myeloid Leukemia Patients <= 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.

Markus Andreas Schaich, MD, Silke Soucek, Hartmut Döhner, MD, Gerhard Ehninger, MD, Arnold Ganser, MD, Gerhard Heil, MD, Rainer Krahl, MD, Jürgen Krauter, MD, Dietger W. Niederwieser, MD, Christina Sauerland, Thomas Büchner, MD, Richard F. Schlenk, MD

Blood (2005) 106 (11): 2374.

https://doi.org/10.1182/blood.V106.11.2374.2374

Published: 2005

Journal Articles

Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.

Dorle Messerer, PhD, Jutta Engel, MD, Jörg Hasford, PhD, Markus Schaich, MD, Silke Soucek, Gerhard Ehninger, MD, Christina Sauerland, PhD, Thomas Büchner, MD, Dietger W. Niederwieser, MD, Rainer Krahl, MD, Jürgen Krauter, MD, Irina Schäfer, Arnold Ganser, MD, Claire Schleich, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2005) 106 (11): 747.

https://doi.org/10.1182/blood.V106.11.747.747

Published: 2005

NARROW

Factors Influencing Complete Remission (CR) Rate in Patients ≥ 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Kinetics of Engraftment and Predictors of Outcome in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL) After Treatment with Low Dose Total Body Irradiation (TBI) Followed by related or unrelated hematopoietic Stem Cell Transplantation

Delayed Processing of Bone Marrow Samples Reveals a Prognostic Pattern of NME mRNA Expression in Cytogenetically Normal AML

Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML

Adverse Immunologic, Cytogenetic, and Molecular Features of AML in Elderly Patients Could Be Overcome by Allogeneic Hematopoietic Cell Transplantation Following Reduced Intensity Conditioning

Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup

The Ratio of Pre-Transplant Serum Ferritin to the Units of Blood Transfused and Not Serum Hepcidin Strongly Correlates with Outcome After Allogeneic Hematopoietic Cell Transplantation In Patients with AML and MDS.

Hematopietic Cell Transplantation after a Low-Dose, Total-Body Irradiation Based Regimen in Elderly Patients with AML: A Multicenter, Multinational, Prospective HOVON/SAKK/OSHO Study.

Pooled Data Analysis of Acute Myeloid Leukemia Patients <= 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.

Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only